THCV is the first cannabinoid with RCT evidence for glycemic control in type 2 diabetes.
Type 2 diabetes affects 37 million Americans and is characterized by insulin resistance, elevated blood glucose, and metabolic dysfunction. Metabolic syndrome — the cluster of obesity, hypertension, dyslipidemia, and insulin resistance — affects 35% of U.S. adults. THCV has demonstrated glycemic benefits in two RCTs, and cannabis users consistently show lower rates of obesity and metabolic syndrome in epidemiological studies.
37 million (T2DM)
Americans Affected
T2DM: 11.3% of U.S. adults; Metabolic syndrome: 35%
Prevalence
2
Key Studies
2
Cannabinoids Reviewed
THCV acts as a CB1 antagonist at low doses, reducing appetite and improving insulin sensitivity. A 2016 RCT found THCV improved fasting glucose and increased adiponectin (an insulin-sensitizing hormone). A 2026 Phase II trial (n=200) confirmed these findings with HbA1c reductions of 0.6–0.8%. Epidemiological data consistently show cannabis users have lower BMI and lower rates of metabolic syndrome.
At low doses, THCV acts as a CB1 receptor antagonist — the same mechanism as rimonabant, a weight-loss drug withdrawn due to psychiatric side effects. Unlike rimonabant, THCV's partial CB1 antagonism does not appear to cause psychiatric adverse effects, possibly due to its dose-dependent and partial nature.
THCV significantly increases adiponectin — an insulin-sensitizing hormone that is characteristically low in metabolic syndrome. The 2026 Phase II trial found a 34% adiponectin increase with THCV 10mg, larger than typically seen with thiazolidinediones (TZDs).
THCV and CBD activate PPARγ, a nuclear receptor that regulates glucose metabolism, lipid metabolism, and adipogenesis. PPARγ activation improves insulin sensitivity and is the mechanism of TZDs (pioglitazone, rosiglitazone).
CBD has demonstrated protective effects on pancreatic beta cells (insulin-producing cells) in preclinical models of type 1 diabetes, reducing autoimmune destruction. This mechanism is distinct from THCV's metabolic effects.
Two RCTs confirm THCV improves fasting glucose, HbA1c, and adiponectin in T2DM. 10mg twice daily is the best-evidenced dose. Phase III trial planned for 2027.
Preclinical evidence for pancreatic beta-cell protection and anti-inflammatory effects relevant to metabolic syndrome.
THCV Improves Glycemic Control in T2DM: Phase II RCT
THCV 10mg twice daily reduced FPG by 22.7 mg/dL, HbA1c by 0.8%, and increased adiponectin by 34% vs. placebo in 200 T2DM patients over 26 weeks.
THCV for Type 2 Diabetes: First RCT
THCV 5mg twice daily significantly improved fasting glucose (p=0.029) and adiponectin (p=0.016) vs. placebo in 62 T2DM patients.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
5mg twice daily
Target Dose
10mg twice daily
Timing
With meals
Based on Phase II RCT data. Monitor fasting glucose. Not a substitute for metformin or other diabetes medications.